Polysaccharide particle mixture

Patent metadata

Field	Value
Publication number	US-10420794-B2
Application number	US-201615389430-A
Country	US
Kind code	B2
Filing date	Dec 22, 2016
Priority date	Apr 24, 2008
Publication date	Sep 24, 2019
Grant date	Sep 24, 2019

Abstract

Tissue and other body structures may be protected using a dry, free-flowing, sterilized mixture of chitosan particles and oxidized polysaccharide particles in sealed packaging. The mixture may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function.

First claim

The invention claimed is:

1. A composition comprising a dry, free-flowing, sterilized mixture of separate rehydratable particles comprising about 20 to about 95 wt. % of chitosan particles containing amino groups and about 80 to about 5 wt. % of oxidized polysaccharide particles containing aldehyde groups in sealed packaging, wherein the amino group functionality and molecular weight of the chitosan and the aldehyde group and molecular weight of the oxidized polysaccharide are such that the mixture of chitosan particles and separate oxidized polysaccharide particles are rehydratable in situ when removed from the sealed packaging and applied in a dry state to a surgical tissue site or wound moistened with bodily fluids such that the mixture of chitosan particles and separate oxidized polysaccharide particles will adhere to such tissue site or wound and will adhere to one another by inter-particle crosslinking reaction of amino groups on the chitosan particles with aldehyde groups on the polysaccharide particles, wherein the dry, free-flowing, sterilized mixture of chitosan and oxidized polysaccharide particles contains less than 10% wt. % water.

2. A composition according to claim 1 wherein the chitosan particles have a number average molecular weight of about 10 to about 500 kDa.

3. A composition according to claim 1 wherein the oxidized polysaccharide particles comprise oxidized starch particles.

4. A composition according to claim 1 wherein the mixture contains about 80 to about 20% of the chitosan particles and about 20 to about 80% of the oxidized polysaccharide particles.

5. A composition according to claim 1 wherein the mixture contains about 60 to about 40% of the chitosan particles and about 40 to about 60% of the oxidized polysaccharide particles.

6. A composition according to claim 1 wherein the mixture contains about 60 to about 40% of the chitosan particles and about 40 to about 60% of oxidized starch particles.

7. A composition according to claim 1 wherein the chitosan particles and oxidized polysaccharide particles are non-comminuted.

8. A composition according to claim 1 wherein the chitosan particles and-oxidized polysaccharide particles in the sealed packaging are uncrosslinked.

9. A composition according to claim 1 wherein the chitosan particles and oxidized polysaccharide particles are rehydratable in situ to form a gel on the tissue site or wound.

10. A composition according to claim 9 wherein the chitosan particles and oxidized polysaccharide particles provide a polysaccharide gel when rehydrated.

11. A composition according to claim 1 wherein the chitosan particles and oxidized polysaccharide particles contain a sufficiently low amount of collagen so as not to pose a potential risk of transmission of or infection with bovine spongiform encephalopathy (BSE) or variant Creutzfeldt-Jakob disease (vCJD).

12. A composition according to claim 1 wherein the dry, free-flowing, sterilized mixture of chitosan and oxidized polysaccharide particles are capable of forming a substantially continuous conformal protective layer over such tissue.

13. A composition according to claim 12 wherein the tissue comprises mucosal tissue.

14. A composition according to claim 13 wherein the mucosal tissue is in a nasal cavity.

15. A composition according to claim 13 wherein the mucosal tissue is in a sinus cavity.

16. A composition according to claim 12 wherein the tissue comprises an injured, inflamed or surgically repaired surface and the mixture assists in returning such injured, inflamed or surgically repaired surface to a normal state.

17. A composition according to claim 16 wherein the return of such surface to a normal state includes reciliation.

18. A composition according to claim 1 further comprising a sustained release therapeutic agent.

19. A composition according to claim 1 wherein the mixture of particles is inherently antimicrobial without requiring addition of a separate antimicrobial agent.

Assignees

• Medtronic Inc

Inventors

• Medina Jennifer G
• Hissong James Britton
• Myntti Matthew F
• Oliver Dana A
• Vaccaro Brian J

Classifications

• A61L2/087

  Particle radiation, e.g. electron-beam, alpha or beta radiation · CPC title

• A61L2103/05

  Living organisms or biological materials · CPC title

• A61K31/717

  Celluloses · CPC title

• A61K9/0085

  Brain, e.g. brain implants; Spinal cord · CPC title

• C08L1/286

  substituted with acid radicals, e.g. carboxymethyl cellulose [CMC] (C08L1/282 takes precedence) · CPC title